INCY
★★★★☆ BuytemplateIncyte Corporation
Healthcare · sector percentile 100
Session move
$112.73
Vol 1.43× avg
85/100 quant · tgt $128.92
RS60 -5.3% vs SPY · ADV$ 210.1M
session 2026-10-06 · Snapshot — not live tape
Since last scan
2026-10-06 → 2026-10-07
Context only — not a buy/sell signal. Built from scan history and cached news/filings.
Snapshot quote
session 2026-10-06 · scan 2026-10-07 · pushed 10-07 13:13 ET · Regular session (stale)
Show quote fundamentalsHide quote fundamentals
- Last (scan/close)
- $112.73
- Previous close
- $114.13
- Pushed last
- $113.93 (stale) · 10-07 13:13 ET · Regular session
- Session open
- $114.13
- Last session range
- $111.67 – $114.97
- 52-week range
- $82.82 – $132.60
- Session volume
- 2,459,391
- Avg volume (20d)
- 1,724,930
- Market cap
- $22.85B
- PE (TTM)
- 14.36
- Forward PE
- 12.89
- Dividend yield
- 0.00%
- 1y target est.
- $128.92
- Next earnings
- 2026-10-27
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes.
If you put $1,000.00 in
1y ago
$1,293.22
+29%
5y ago
$1,710.88
+71%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
Market briefing
Curated digest — not a trade signal. Headlines and links as provided by the producer.
- Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).
Yahoo · 2026-10-01
- Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Yahoo · 2026-09-25
- INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.
Yahoo · 2026-09-25
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — INCY scores 84.85/100 (Buy) with revenue growth at 37.7% and a multi-factor profile supporting the current ranking.
- Risks — Key risks for INCY include valuation compression, sector rotation, and any deterioration in earnings momentum or balance-sheet leverage. Context: cached next earnings 2026-10-27; cached Form 4 cluster (count, n=5, latest 2026-10-05); disclosure reasons form4_cluster_ambiguous.
- Target Upside — Consensus implied upside is 14.4%. Category 'Buy' suggests monitoring position sizing against the 100-point model thresholds.
Score History
30 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-10-07$112.73−$1.4084.8Buy
- 2026-10-06$114.13−$1.1784.6Buy
- 2026-10-05$115.30−$1.8485.4Buy
- 2026-10-02$117.14−$4.2184.9Buy
- 2026-10-01$121.35−$1.8586.1Buy
- 2026-09-30$123.20−$1.6286.4Buy
- 2026-09-29$124.82+$0.9386.0Buy
- 2026-09-28$123.89−$0.5586.3Buy
- 2026-09-25$124.44−$0.2088.4Buy
- 2026-09-24$124.64−$2.2990.2Strong Buy
- 2026-09-23$126.93+$2.2889.8Buy
- 2026-09-22$124.65−$0.6690.4Strong Buy
- 2026-09-21$125.31−$2.3190.3Strong Buy
- 2026-09-18$127.62+$2.8789.6Buy
- 2026-09-17$124.75+$3.0190.4Strong Buy
- 2026-09-16$121.74−$0.4591.0Strong Buy
- 2026-09-15$122.19+$0.7288.2Buy
- 2026-09-14$121.47−$1.8188.4Buy
- 2026-09-11$123.28−$2.7389.6Buy
- 2026-09-10$126.01+$1.6190.1Strong Buy
- 2026-09-09$124.40−$2.3590.5Strong Buy
- 2026-09-08$126.75$0.0089.9Buy
- 2026-09-07$126.75−$1.2589.9Buy
- 2026-09-04$128.00−$0.8389.6Buy
- 2026-09-03$128.83+$3.8289.6Buy
- 2026-09-02$125.01+$1.7990.2Strong Buy
- 2026-09-01$123.22−$1.1590.7Strong Buy
- 2026-08-31$124.37−$3.3790.3Strong Buy
- 2026-08-28$127.74−$0.3889.6Buy
- 2026-08-27$128.12—89.6Buy
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 80.6%
- vs 20d (z)
- 1.89
- Short vol
- 1,051,196
- Status
- ok
Squeeze pressure score
full41/100
- Short leg
- 51
- Call leg
- 35
- Activity
- 6.1
- Call vol share
- 38.7%
- PCR (vol)
- 1.59
- Call OI share
- 26.4%
- ATM IV
- 51.6%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
Disclosure score
Rule-based News / Insider / Earnings legs from cached SEC filings — context only, not beat/miss or a buy signal.
Disclosure score
0
- News
- 0
- Insider
- 0
- Earnings
- 0
Signals below are rule hits from cached filings — Risk / Constructive / Attention. Attention is not a bullish call. Linked chips open the SEC original when available.
Attention (~)
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
Earnings surprise (quant context)
From Yahoo/public fundamentals cached on the last quant scan — not part of the disclosure event score, and not a buy signal. Figure can lag the latest print.
Last reported surprise +0.4%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-10-27yahoo_calendar
- Last earnings
- —
- SEC ↗42026-10-05
FORM 4
- SEC ↗42026-10-02
FORM 4
- SEC ↗42026-10-02
4
- SEC ↗42026-10-02
FORM 4
- SEC ↗42026-09-24
FORM 4
- SEC ↗42026-09-17
FORM 4
- SEC ↗8-K2026-08-31
8-K
- SEC ↗42026-08-27
FORM 4
- SEC ↗42026-08-20
FORM 4
- SEC ↗42026-08-14
FORM 4
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.